Recent PLSE transcripts
Associated PLSE filings
| Brian Dow | SVP and CFO |
| Darrin Uecker | President and CEO |
Good afternoon, ladies and gentlemen, and welcome to the Pulse Biosciences Q3 2018 Earnings Conference Call. At this time, all participants are in a listen-only. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Brian Dow.
call. your begin may You
Great. Thank Pulse And to afternoon, operator. third quarter Good Biosciences call. everyone. XXXX welcome you investor update
to we presentation, during today’s webcasting addition presentation today’s will our call. In be audio
the our would and who the Events the the can webcast to For www.pulsebiosciences.com link section under participants today’s of like to relations tab at presentation, Events follow you Calendar. find website investor and on News
Duggan, General Chief the me with are Uecker, Executive today of Officer; and and Vice Bob Dermatology. of On Ebbers, the call Directors; Chairman our Darrin Board Manager our our President Ed President of and
our Before we scientific, projections, financial to plans, will we remind and clinical include applications products like forward-looking financing call, events. including future making products to today’s These statements. such on and operational, begin, be intentions would other our of and you uses I and the plans, that relating expectations
reliance subject and mostly report of forward-looking uncertainties not XX-Q. such are statements, Exchange and to described information future update on to a of place should filed XX-K as Investors are result reports. risks recently differ more materially are events. may disclosures risks undue assumptions, These new uncertainties from on Securities actual or fully reference which results You Commission and undertakes Form these in our other results. no obligation Form number encouraged and on and and a in those to and filings Biosciences quarterly Pulse forward-looking statements uncertainties,
to materially Darrin shortly that audio website the like electing be available live Investors forward-looking on on change I and the use call our today’s President conclusion Executive is are call. recorded of replay cautioned will of presentation Officer, call remind Uecker. after section at may the Chief the and the and the that I webcast replay would you www.pulsebiosciences.com, to call addition, completion of the differ now call. turn over or our to statements after Investors In live today’s the made for being
Thanks, join call. everyone, thank Brian. for you today’s on time to Good and afternoon, taking us
and Stimulation We as highly Nano-Pulse Nano-Pulse of a electrical towards our proprietary differentiated optimism continue ultrafast to proprietary bringing great pulse that up Stimulation and make millionth market pulses to work second. is a platform. our energy from durations uses to we progress a with billionth builds platform
of membrane. energy dysfunction to mitochondria pulses including NPS leading mechanism the This of cells the by reticulum, and without internal amplitude and biophysical Our enter interacting and of nontoxic disrupt structure cellular cell NPS and unique, and of speed a cell the physical function pulses cells. the endoplasmic outer brought the integrity non-thermal death our with the disrupting organelles, about mechanism is
previous the utilizing human to functional the are the tissue, in While that therapeutic think regarding use time of important System, platform NPS we our the platform, no consistent our proprietary calls, we have on delivered that endeavored in our deliver cells point pulses not at first tunable of with human with to did PulseTx a deliver which develop as they system tissue combination to the for lead capacities the we NPS that In differentiated treatment medicine. acellular believe this platform cell-focused unique, directly medicine. healing. And of when our bringing while effect I highly NPS will NPS, we and used a any acellular a point other we this of surrounding in it’s system preserving Nano-Pulse aware we our the out short, can platform a clinic, strategy communicated that first with tissue tunable Stimulation the protein NPS into supports would Superficially, message have applications. we market. take effect In internal our structure have to such function affect treatment collagen,
over XX on to and further our proprietary patent is a other portfolio position, Our worldwide evidence maintain comprehensive patents. patents these energy of long-term future and sources, based of differentiation we strive from
that very data and from that we are and would pleased demonstrate pipeline ongoing stated and in additional clinical commercial expanding NPS Today, in And of first would and compelling of a to unique database executed over significant studies our several The our years, evidence the commercialize compelling supported. mechanism based and efficacy the opportunity our safety we in the and our of that the of growing of a selected platform aesthetic as two unique enabled benefits across announce platform. NPS also us we last KOLs. treatment will strong on And action We markets we the have safety, market then, then efficacy have and launch we the clinical market applications studies demonstrate with to pilot of number indications, of dermatology. where studies have platform. we the help procedure NPS completed clinical
skin, value the of in the over very the two and clinical research data last group excellent surgeons this this available Based United top action and data guidance board today, half are years focus the the of highest the unique and We we are months anticipated for dermatologic aesthetic the procedures. this we research pipeline paying with new commercial of of treatment I differentiated roughly planning of of few common those of skin guide and applications the in highly the cash targets. States clinical in in non-thermal launch size future lesions, specialty advisory closely use with our on the to NPS the results planned launch dermatology in been of to in support and in benign developing support of of on have working review a XX our half will second cancer a moments. or very and from XXXX the our our for prioritize specialists to mechanism treatment opportunity
Before benefit our up I to including out that, had developments important applications to it’s in this point other clinical speeding NPS prioritizing the opportunity, research of immuno-oncology. that commercial for that our the do led additional
extensive patients. has action which experience, allowed skin NPS the the mechanism establish of human safety, cycles in X,XXX us to over includes in now and Our symmetry human
Basal move Our rapidly. Carcinoma in is cancer study, our dermatology first more how Cell a human of allowed in cancer to progress human our example us an has into
be of exciting opportunities that been future our progress near to continuing the a market term, clear at is opportunity We relative paramount. that company. viability. access that have important pursuing viable Pulse a in towards also And can while is Biosciences is Viability we to mission pipeline maintain an significant
decisions, market. when growth are are treatments skin spend The this I’ll certified an most lesion an years. aesthetic these to for interest benign self-pay are doubled Surgeons cash growing, dermatologists procedures, to patients. Dermatologic spent board paying X,XXX This are the enhancing that patient devices covered of specialists appearance Society XX% aesthetic a removal purchasers is enhancing or the of market of it growing for of the have annual of dermatology those removal leading a not market The the conducted market about a last consumers cash-paying procedures, time that same procedures. comes paid the of of procedure, confirmed some research influencer reported of Now, consumer where are ASDS group procedures are In this over survey appearance In X,XXX of talking United consumer out-of-pocket exciting aesthetic cash-paying in and are States, five in recognition of cash is large by has seeking at paying the considering energy-based ASDS fast American procedures large benign XXXX, and Americans over skin than their concentration which insurance. and approximately that estimates to advice In short, recent patients that dermatologists including number that lesions procedures an on number by typically industry These driven this of research more billion procedures. skin XX%. for one consulting procedure skin that to is improve done. consumer with rate According and $XX on market of procedures. aesthetic
initial with the the mentioned cancer as well to indications. I that to pave top clinical spent the build of NPS data and as difficult-to-treat couple on benign a years that not we dermatologic multiple mechanism skin and results specialists action, efficacy set based the lesions and skin these exciting represent have safety to differentiated additional surgeons working As previously, applications highly of has in last the our opportunities only demonstrated way
outcome. cells tissue, study while The dose-ranging process that the leading first was in step to our demonstrated and NPS safety acellular sparing target good skin to the cosmetic ability of this
our layer prior top The skin NPS slide an of our to XX-hourss purple NPS. here the with treatment. images a The along left on the show image microscopic are is the is you middle treatment cells. tissue the epidermis, following which of of images after epidermal as where are you with healthy of see seeing dark The If skin. skin presentation series you image skin
and Importantly, dermis treatment. the epidermis remain below intact after
These slide feature highly epidermis the both key suited acellular impact non-viable their and underlying was chosen in epidermal represent the be replaced that opportunities apart seborrheic our data, which demonstrates and hyperplasia. these epidermis, growing by that modalities, the dermatology an makes further because structurally case ghostlike the cells were the the new compared the we advisors breaking initially. NPS. believe could The cells and those in evidenced as as is it ability One top that freezing, of chart term and of and conditions as off our of our differentiated our success, Based down far skin This would lifted the with would on we NPS the ranging a skin and treatment NPS, can is difficult such shows on lesions, keratosis this for modalities cells of they of alternative NPS. were valuable while in the NPS benign of to in are study significant the sebaceous with These right treat the represent is slide. and longer for and mechanism sparing good are This feature to new However, dose affects in image should is the showed as is worked that prioritized left early if healing viable, it appearance. tissue highlight We shown lesions tissue unique prevalence in where burning. lesion which the and a spares by no imagine the epidermis dermis. without dermis of important cellular or tissue acellular the to the uniquely lifting primarily of tissue cells and our of below. target identify we to we epidermis. it list with this process At epidermis are the mechanism identified indications off epidermis if on be treated XX or
Our first or study benign seborrheic skin lesion. keratosis indication the within most SK, common
patients suggests dermatologists that the as U.S. X interested in are treatment. as many are there in Our by and seen research aesthetic million being
also exceptional very poor looking to study, the good XX% advice the study treated included treatment. with patients events. mostly the or worse associated NPS cleared cleared the only with lesion about efficacy However, of when treatments, This skin this current patient. patient present. after SK a single initial per patients procedure We and lesions our was XX% receive showed we leave rate an lesions the no XX reported X these remove tolerability with due but electrodessication as or adverse which with suggests treatment cosmetic of cryotherapy believe safety In can or outcomes such than that SK is
of data the SK that treatments. exciting Our results agent other study is beyond as multiple efficacy single efficacy a lesions topical the XX% usually paved epidermis. way superior treatment and important rate, the in showed recently the commercial with opportunity after present approved from for are also it This that
that gland enlarged lesions to oil dermis. treat to energy study condition from called was This the cellular for that and of cause other resides in to the dermis. without outcomes dermis in without technologies a significant the thermal mechanism sebaceous collateral the research or X.X the current that treatment. reach glands is SH Our that the any receive surrounding due dermis scarring million or a area. this The patients are modalities epidermis cosmetic the skin treatment general, spreading hyperplasia approximately particularly to deeper SH. dermatologists, damaging XX% destruction facial the the than their believe can difficult We seen damage thermal being a benign type risk below of next be to In eliminate only indiscriminately our market original is are worse or structures to objective for sebaceous negative negative dermis underlying lesion lesion. thermal sebaceous explain or the its by with Damage because unable helps common cosmetic large of to outcome suggests indication of deep the is
into to lesions damaging research dermis, a Our has has cellular lesion. without NPS a targeting the it modality that penetrate target and the effective treatment highly for unique and proven making unique potentially ability dermis surrounding SH
that study treatment XXXX. available SH in quarter expected we by Our complete the previously the end with of ongoing. data is We to stated third being
to we set XX the We patients third report treatments are quarter on enrollment in the and full data the expect pleased and as the to end we follow-up of by of year. anticipated, ongoing report is completed
took that set completed reported We SH the lesions clear soon. to XX% XX-day period, forward or look as on interim such of efficacy result addition, clear very full treat. over we the the at lesions follow-up investigators, for XX% In reporting a of data a to promising lesion have look difficult mostly the and an first those been by
up data However, capable issue, are ability the we the our other showing NPS from data early treat study the Diego at identified Vic patients based feasibility is Ross. lesions the where evidence San to is This one dermis of top feasibility underlying started Based study study the sparing planning This for conditions to the are the in and of epidermis at recently patients. of cutaneous with results on NPS are study center problems executed the a Warts acne. the continued in treatments as the while down from eliminating we glands results sebaceous on XX the prestigious that will in to being warts. the Health such dermis, seeking glands consistently enroll sebaceous currently the Dr. in dermatologists. Scripps and SK of
early cutaneous completing the to report XXXX. designing indication data in expect a enrollment during QX of We XXXX half of positive show results first study out anticipation safety the In from QX study, to multi-center this and next in on year. warts in we’re early after the efficacy
move opinion our gland sizable gland the The potential garnered integral glands, in opportunity. most around sebaceous significant exciting need the plays study interest acne. other study an results commercial hyperplasia gives And ability involving acne. in patient our treat confidence area addition, from In role our to treat sebaceous into early this key to as to conditions the SH NPS sebaceous of sebaceous have evidenced the us of leaders notably forward and in
and parallel we next generation the providing system unique, NPS drug-free look CellFX have into developing property to the as our System. called first In patients. therapy Our the to program these forward potential We been year. clinic additional information we commercial by of this platform the clinical advance with programs, has this NPS the end
when the treatment enables and in variety a shapes into up the in a cart you treatment sizes physician including system the image use can to slide enable the hand lesions CellFX of wirelessly piece. It’s easily surgery room of we plugged tips. CellFX center treatment and This matter is and treatment system with automated small presentation, is use of clinic The see room minutes. the tips and many single a System, they’re family engineered System connect what from outpatient office manufacturing wheeled demand to or a call or the of utilized. to partners ability be anticipated relatively you’re of of our a patient manufacturing designed set skilled used meet If being cost the a effectively that underlying and on dependent to was contract settings The treatment to in can hospital. managing goods. ensure leverage facilitate of settings while viewing for The system tip
System a In involved This as The successfully treatment CellFX in a physician to implementations dermatology XXX(k) We aligns revenue would more XXXX, a and click appropriate indication, FDA touch to for The a clearance revenue such and support for gained on model. this Biosciences conversations and basis. our or charge difficult plan has XXX(k) the of Pulse by to of we required capability to used has past. out with those addition, on the per procedures. clinical clinical others one in allows I functionality incentives the treat basis opposed to been model model studies look and will dermatology. on value-based cash-paying to also FDA revenue the it the pursue these price Ed ensure indications President click be and in employed CellFX the SH working treatment in to tip lesion speak. lesions. clinically based Based This data. submission adjusting we lesion the patient, for our the per Manager per use previous all forward with for the pricing, and provide our knowledge space, into rolling per interactions, Vice has us primarily SK is strategy been our our the specific the regulatory This believe business used to been a and includes the data. in model cosmetic General we’re the successfully and path on as a Ebbers, for Dermatology successful of quarter to now from and we aesthetic
this Entering key that timeframe. will our the And are of for with of and commercial clinical mechanism elements the opinion early Number our yield look dermatology QX opinion collaboration XX study to in treatable four launch. CellFX of System strategy number submission also a in early expansion include top clinical will there receiving are contribute we with that adopter our studies agency. wave at market, success the the aesthetic filing infrastructure key peer-reviewed acceptance utilization journals. system for market. leaders we drive preparations towards four, from proven the commenced planned and clinical planned three, utilization guided XXXX CellFX early proven success. have strategy with XXXX Number marketing number sales has action This our that We the of is will with two, the the the clearance our and one, for next podium strategy of system installed our the System medicine in study activity priorities And leaders our investment, close in will applications around ever-increasing the scientific sales both will and each Number a aesthetic of doctors. will organize for system. and procedure increase
Our the value. revenue stream scales that model model click in installed each system, installed new a each provides increase proven usage trials clinical recurring that business per and for a is This system. clinical will per business application and builds
We sales, launch. out training for anticipation are building in next year’s marketing our team and
revealed applications lesions we for clinical research are anticipate we a data CellFX our NPS on sizable future Our well-suited and generating mechanism. the currently addressable that for market will be
they the near-term rates. utilization that of provide pipeline worse outcome. these that CellFX choices, our clinical mainly applications available improved the increase believe For we extreme today, and system our the leave just a when the our We with started. patient of or cosmetic favorable application use beginning extreme to many have are These solution, off cold heat, removing NPS of healing planned will than lesion lesions significantly the
up with study. so applications that system installed will goes each our per over expand we We application new utilization time
promote study treated types for help solutions to dermatologist recurring as address create an offered to patients expect with applications well aesthetic the offer relationship practice evolves be Over aesthetic not beneficial as soon Biosciences we that modalities. new into technologies that aesthetic they’re to Pulse and allow and available. new are mutually as this with will current more a revenue new the model continue lesion We and time, that
powered range devices, base in We price application the at $XX,XXX, is for of spectrum system. price the new end aesthetic and the point out expect the each low system same the of initial of be can which
unique lesion offerings Our new Over to of I the sharing efforts per to like in time, every of our to advancement tip applications in allows now us revenue original we our turn without would participate make and a treated. model patient treatment profit expand our system. modifying sharing research technology click we can benefits the immuno-oncology. as
strong the NPS market cancer, in our in like effect at as efforts play this [ph] that of has mentioned field I the areas focus previously. exciting a role vaccine aesthetic had potential our to dermatology on such support As has the deliver treating it of start turned commercial in We have our in discussed as can remarks, of we believe prepared we that still preclinical immuno-oncology and a other now initial and this. a foundation evidence our
a However, invest longer this term and our to research. preclinical in opportunity is continue we
Our NPS understanding current optimized adjuvant, the without in use believe malignant of better efforts to maybe are cancer effects NPS focused on our and dose optimization preclinical human. systemic enhance can research in for how important with is that and this of treatment. combinations an We
we dermatology therapeutic demonstrate some and NPS safety an but making it cancer. Pulse treatment. allow effect developments to are our high This those BCC safety study all result us look can patients experience taking is were not ways for therapeutic opportunity, and done up to as move our skin dermatology we Carcinoma of builds follow-on that excellent in This the of demonstrated utilize study sets QX of a it both effect, at to Cell our NPS do will studies, This we skin. human eliminate aimed currently Thanks response group the is the work our us the a Biosciences lesion executing form our in other and cancer we a our endpoint patient we in or ability with has oncology and is at represents comes treated dermatology first the study plans the and of important profile NPS allows are step this study BCC and us immune the continues the to in have a our investigators quickly study As and move a on we to so believe most in unique dermatologists, that in an already oncology. us also exciting in as study able to and have NPS We in are is move quickly first Basal tolerability endpoint. advisors, in a and dermatology enables BCC changes to data quickly a our in. prevalent in therapeutic the study by follow-on between of to skin also into bridge for BCC, these call, their continue advantage where mentioned and NPS been we cellular of Because to using skin prestigious our today. NPS on cancer
pathologist is incredible project. microenvironment resource Pierce Fred analyze with Dr. this the is in to changes have samples board Pierce and working working Cancer are and BCC be destruction the lesion in certified Hutchinson Rob tissue response. immune and Dr. to of changes in the anatomic and in In Research the the immune addition, evaluating pleased the tumor to an we expert Center treated Seattle a cell an who on assess is
nature. study dataset in first therapeutic available of We complete will the and a important discuss XXXX. to lead the review likely and study our expect have that to to will enrollment turn may follow-on upcoming a by through recent cancers regarding I’ll treatments in milestones. quarter call This metastatic BCC this in filings highly fundraising discuss return another end data be our this to also now outcome year to complete to to a to demonstrate are the in I Brian of financials. in then more and over
do proceeds forming extent our offer the registration to $XX and we commence rights offering, assuming statement filed beginning the conducted. XXth, After that the subscription the the Thanks, happen part for to we or financial on filing results file then today with with We October raise of to on declares registration as My the final will announce set rights whether available. with amendment, S-X we of registration to the in is on as is the govern SEC this discussion a statement million. to state week, offer, qualification there comments under of registration the Any offer all of solicitation such today not will be jurisdiction unlawful plans first will a only be securities nor any filed provide or on or means to in to or start Last and quarter. sale buy, offer other the statement intention going Form an constitute prior such SEC its effective and publicly and expiration completes statement price and state subsequent that as cannot is date, is offering it registration when laws the registration upto an my Darrin. Once offering any will Pulse a documents record the and Last of gross we it discussing but may in commencing any week’s recently will Biosciences dependent sell solicitation to be offering to pursuant the once offer any which a offering prospectus information proceed and third of jurisdiction. of the it proceed our financing subject encouraged if of sale statement a or rights the security any review review, remarks would by the and declared amendments commentary date. outlined I’m at made being statement. by of Commission. the reviewed and process are Exchange a statement. stockholders registration read All the registration effective prospectus by Securities and will any effective, any
of statement, under will rights proposed of in record a stockholder be the the their right proportionate entitling issued each the offering. in rights right number registration the to as Next, shares discussed to basic a subscription offering, purchase holder non-transferable
availability is allocation have the rights the effective. described to has subject as stockholders oversubscription other statement that oversubscription shares the to been acquire unsubscribed exercise This of recap, dates, registration exercise not be would Duggan, which his To fully declared the common amounts binding and a wish this shareholder X% record additional acquire For to point issued to their his example, fully right would be as S-X shares I right $XX.X statement. among and further limitations registration Key the who rates in and and in briefly our right of date expressed in formal shares. exercise the the commitment to record we exercised date the pricing are the will subscription of have set has an read statement. have right that right to all expiration out, not relative has ratio afforded subscribe Bob the intention nor encouraged a approximately to Chairman oversubscription registration right, Stockholders basic or basic stockholders to not of regard. for related stock disclosed carefully set, grant. we X% largest holder million the have date including been on the offering. to basic and filed made documents opportunity but a may All their our
ended quarter XX, Turning now for September the operating XXXX. to the results
a quarter. XX% in totaling as increase the investments the resulting at that increase million, of quarter continued attributed of as progress of BCC XXXX, ongoing the cash over million our our the progress and $X.X to and $XX During the third development used development early million. our the cash October, commencement studies generation NPS introduced and second and recently study due research system. our programs, ongoing preparations for clinical support of used development totaled the end clinical work quarter and increased ongoing drove of for cash CellFX headcount the development of made to $X.X cost during system expanded increased can trial of in as reflects the and and This next in quarter the used SH growth business, activities the the cash The commenced investments be NPS to the well
purchase $XX million the and effective Bob completion our or financial advances have XX, continuing million In loans up to XXXX. Such of the we form for occur million irrevocable also to November addition at to from support us. of our of Chairman, XX, to earlier $XX take cash or to may equity, of totaling $XX on Duggan equity received the financing hand, support of September commitment investments a
of our comprised remains common months. operations fund of investments the over outstanding stock. Bob’s our and in to current With commitment, free debt, is Our for of and cash sufficient next balance liquidity have stock with XX shares excess we sheet solely accompanied
the counts loss contributing loss operating Similarly, nine-month reflects clinical X personnel. $X.X third On year, at $X.X recently R&D increased A or loss in increased quarter September this million increased the year-to-date XXXX. quarter million an and year The the for of XX and to and of $X.X protocol expenses engineering year-to-date increase September and growth XX, over the in headcount introduction CellFX Also, operational $XX and XXXX. component ongoing To period. completed third design, for to a million year-over-year million periods million portion enhancements going quarter loss expenses our research, $XX.X commercial then, future patients in to XXXX and XX% Headcount during reflects of from a an million increase basis, commenced XXXX activity the approximately XXXX system the third million million relating results intervening stock-based of XXXX trials, XX, R&D the in XX%. non-cash the net $X.X Company totaled and in end XX $X.X respectively. ‘XX, to number for to finally reflecting ongoing contributing for and the expenses the and or patient studies; similar will to Again, XXXX, million reflecting breadth XXXX increase expenses as reflects increase in anticipated studies, trial significant of during has XXXX to in ended for support million the at with soon and increased headcount the reported increase million a in at of Research and for of and in the $X expense XXXX XX. in net stock-based to development the are compensation to XX and in at compared reflecting the increase net net evidential periods respectively. XX, earlier. for September loss progress prototyping of to NPS for XX for continue XXXX. XXXX. to preparation addition for $XX.X in half of commence charges expenses, increased preparation forward the both clinical periods development increase $XX.X XXXX of to of $XX.X increases from September enrolled third to ongoing increasing perspective, $X.X Net from loss in and expenses future quarter clinical prototyping second reflect of the XXXX $X.X of from system; development reflecting ongoing our development December charges preclinical activities. in the million of building Turning the XXXX, support Net significant million, increased R&D the XX, furthering CellFX the compared of our to be the of increase $X.X R&D to future increases for during studies, XXXX. put XX% of XXXX, prior of results. [ph] totaled or R&D a R&D compensation of includes incurred, million, expenses and the
general XX%. The XXXX, from at basis, quarter XXXX. a or $X.X G&A XX, for year-over-year end the to On compensation, XXXX. G&A of increase expenses XX, of X an September of as million from an to the of million the $XX.X increased reflecting reflects to G&A increase and to $X.X quarter-over-quarter XX%, quarter headcount million at increased the million compared million, increase of $X.X of in to for XX third million year-to-date increase $X.X expenses XXXX, up administrative $X.X expenses. Turning or increased third and
a ongoing fees reflecting XXXX operation, increase. expenses reincorporation general passed year-to-date a in to also and strategic and to corporate G&A and for support. property the basis, legal $X.X reflecting to additional increase On week QX in significant for matters related be intellectual growth Delaware, between the increase stock-based statements and planning activities our corporate the strategic million XXXX planning development can XXXX included In consulting filing addition, of matters. and in initiatives legal registration the preparing contributed compensation reflected expenses made and expenses year-over-year increased estate, attributed our comparisons last in registration with compensation, proposed reflecting services, increased in property and assisting predominantly the intellectual Consulting resources, expenses matters outside SEC financings, and associated
of the Going with G&A, expect reflecting previous the approximately initiatives clinical development the studies operational total guidance, we Consistent support for measured and operational million. $XX forward, increase. cash we needs of XXXX as in anticipate tempo system our to used our organization growth
our Finally, call. received before on that to revisit all I my not need to I certain multiple previous from Pulse the a requirements, conclude investors listing response remarks, regarding briefly wanted questions does notices NASDAQ’s in brokerage discussion sties from of ongoing
a our was listing or period NASDAQ audit resulted the XXXX, in has the until reduced independent non-compliance ongoing Meeting us requirements. cure earlier to NASDAQ directors. with of next July provided This XX, of Annual membership committee July During our XXXX. two our
to is time. Darrin. that remediating concludes call turn advance committed will This Our sufficiency my Directors remarks. the the now Board of I of prepared well to in back
of to our prepared end I couple like Brian. points would reiterate important Thanks, milestones. and remarks, reiterate our To a
application. mission in a viable a to second, relatively where unmet commercialization And down our number pursuit our focus deliver our in market. a dermatology end, on our we not slowing commercial are NPS’s believe skin in needs commercial path become lesions quick of with company. we aesthetic is is unique of immuno-oncology opportunity to significant dermatology, mechanism aesthetic can pursuing toward And First, a this
it In of establishing well skin by applications enter study against our to NPS and current to helps of as believe is an studies. in previous by human mechanism into fact, which is accelerate BCC studies safety our evidenced clinical those and leveraged action the ability we our initial
Now, with to Last end of study complete data XXXX. SH we I in reported that we third would communicated our the milestones. would our in the being treatments quarter by quarter, reiterate like
to all data QX report to in we’re looks and Again, as share is allow data track to were completed final year. interim report excited the by the of end set are very and to promising. complete pleased on We follow-up data follow-up to treatments the us the
year. The to acne start second half study and BCC of plan warts in study cutaneous We started studies this feasibility feasibility also in the an talked year, we of the about starting additional July. before the in and study the we end October,
XXX(k) study for BCC We’ve be in expect one XXXX. to that previously warts track continue on specific We quarter XXXX, study our in out a plan one to to our dermatology for and we important submit indication report on quarter FDA to and milestone. in said we
quarter XXXX. be to the it expect we fact, In early one part in of
used have get system half FDA once the in launch for commercial second through of We is our the XXXX, process. in track and next on CellFX regulatory generation it we clinic, the
prospects update. open at Pulse our progress would excited That call are to and remarks. to investor we time our listen Operator, like prepared on in our to about and the We our taking concludes Biosciences appreciate you now the questions.
just and in that thank to Thank I’d and last Pulse you you call. just for that a slide a platform. overview slide, with the like quarter’s everyone is with strong this Biosciences operator, is participating reiterate which an company you, in is position leave proprietary a
conditions. clinical We treat to dermatology data have very excellent difficult in aesthetic
in We have a near-term commercial dermatology. opportunity aesthetic
future We of a very have immuno-oncology, Directors. are about which several identified have Board also management we excited got and strong very applications, in we and
you call for much you with that leave today’s thank and will I very participating. with So,
wonderful day. and you your Ladies today’s and gentlemen, concludes a participation have Thank this conference.
You disconnect. may now
We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.